Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Auxilio Mutuo Cancer Center /ID# 157853
mi
from
San Juan,
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Auxilio Mutuo Cancer Center /ID# 157853
mi
from
San Juan,
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
St Jude Medical Center / St Joseph Health /ID# 210183
mi
from
Fullerton, CA
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
St Jude Medical Center / St Joseph Health /ID# 210183
mi
from
Fullerton, CA
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Marin Cancer Care /ID# 210408
mi
from
Greenbrae, CA
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Marin Cancer Care /ID# 210408
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center - West Hollywood /ID# 210819
mi
from
West Hollywood, CA
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center - West Hollywood /ID# 210819
mi
from
West Hollywood, CA
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Univ Maryland School Medicine /ID# 159721
mi
from
Baltimore, MD
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Univ Maryland School Medicine /ID# 159721
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Gundersen Health System /ID# 210807
mi
from
La Crosse, WI
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Gundersen Health System /ID# 210807
mi
from
La Crosse, WI
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Aurora Health Care, Aurora Cancer Center /ID# 209612
mi
from
Wauwatosa, WI
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Aurora Health Care, Aurora Cancer Center /ID# 209612
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Plantation, FL
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Plantation, FL
Click here to add this to my saved trials
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Melbourne,
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Melbourne,
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Winship Cancer Institute Emory University School of Medicine
mi
from
Atlanta, GA
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Winship Cancer Institute Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Charles A. Sammons Cancer Center at Baylor University Medical Center
mi
from
Dallas, TX
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Charles A. Sammons Cancer Center at Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas
A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas
A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
John Theurer Cancer Center-Hackensack Meridian Health
mi
from
Hackensack, NJ
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
John Theurer Cancer Center-Hackensack Meridian Health
mi
from
Hackensack, NJ
Click here to add this to my saved trials
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated:  12/31/1969
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated: 12/31/1969
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
Click here to add this to my saved trials
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Click here to add this to my saved trials
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Bergen
mi
from
Montvale, NJ
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Bergen
mi
from
Montvale, NJ
Click here to add this to my saved trials
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
Phase II Trial of Arsenic Trioxide and Dose-Escalated Cholecalciferol in Myelodysplastic Syndrome
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
Phase II Trial of Arsenic Trioxide and Dose-Escalated Cholecalciferol in Myelodysplastic Syndrome
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy
An Open-Label, Pilot Study of Daptomycin vs. Vancomycin for Treatment of Gram-Positive Bacteremia in Neutropenic Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy
An Open-Label, Pilot Study of Daptomycin vs. Vancomycin for Treatment of Gram-Positive Bacteremia in Neutropenic Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated:  12/31/1969
Metro Health Cancer Center
mi
from
Wyoming, MI
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated: 12/31/1969
Metro Health Cancer Center
mi
from
Wyoming, MI
Click here to add this to my saved trials
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare, P. C.
mi
from
Peoria, IL
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare, P. C.
mi
from
Peoria, IL
Click here to add this to my saved trials
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hopital and Clinics
mi
from
Iowa City, IA
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hopital and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated:  12/31/1969
Integrated Medical Professionals, PLLC
mi
from
Lake Success, NY
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated: 12/31/1969
Integrated Medical Professionals, PLLC
mi
from
Lake Success, NY
Click here to add this to my saved trials
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated:  12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated: 12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated:  12/31/1969
GU Research Network, LLC
mi
from
Omaha, NE
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated: 12/31/1969
GU Research Network, LLC
mi
from
Omaha, NE
Click here to add this to my saved trials
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated:  12/31/1969
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated: 12/31/1969
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Click here to add this to my saved trials
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated:  12/31/1969
University of Arizona Cancer Center at Dignity Health St. Joseph's
mi
from
Phoenix, AZ
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated: 12/31/1969
University of Arizona Cancer Center at Dignity Health St. Joseph's
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated:  12/31/1969
IU Health Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated: 12/31/1969
IU Health Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated:  12/31/1969
Clement J. Zablocki VA Medical Center
mi
from
Milwaukee, WI
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Status: Enrolling
Updated: 12/31/1969
Clement J. Zablocki VA Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Center at University of Michigan
mi
from
Ann Arbor, MI
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Center at University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Status: Enrolling
Updated:  12/31/1969
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Status: Enrolling
Updated: 12/31/1969
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials